Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib

Tyrosine kinase inhibitors (TKIs) targeting signaling molecules downstream B cell receptor (BCR) are powerfully spreading in the therapeutic landscape of B cell lymphoproliferative disease, due to a manageable toxicity profile and encouraging clinical effectiveness. In particular, ibrutinib, previou...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Hematol Oncol
Egile Nagusiak: Maffei, Rossana, Fiorcari, Stefania, Martinelli, Silvia, Potenza, Leonardo, Luppi, Mario, Marasca, Roberto
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2015
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459446/
https://ncbi.nlm.nih.gov/pubmed/26022368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0157-x
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak